Dendritic cell-based immunotherapy for prostate cancer

Dendritic cells are unique in their ability to stimulate naive T cells. These investigators have developed a prostate cancer vaccine using autologous dendritic cells as a vehicle to present prostate antigens to T cells in vivo.

Saved in:
Bibliographic Details
Published in:CA: a cancer journal for clinicians 1999-03, Vol.49 (2), p.117-128
Main Authors: Tjoa, B. A, Lodge, P. A, Salgaller, M. L, Boynton, A. L, Murphy, G. P
Format: Article
Language:English
Subjects:
Cancer Vaccines - therapeutic use
Cellular biology
Combined Modality Therapy
Dendritic Cells - immunology
Humans
Immunology
Immunotherapy
Male
Prostate cancer
Prostatic Neoplasms - immunology
Prostatic Neoplasms - therapy
Vaccines
Citations: Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dendritic cells are unique in their ability to stimulate naive T cells. These investigators have developed a prostate cancer vaccine using autologous dendritic cells as a vehicle to present prostate antigens to T cells in vivo.
ISSN:0007-9235
1542-4863
DOI:10.3322/canjclin.49.2.117